The Alaska Permanent Fund Corporation (APFC) focuses on building a diversified, global private equity portfolio, including venture capital, buyouts, real assets, and distressed credit, to maximize risk-adjusted returns and ensure long-term sustainability. Their strategy involves investing through primary partnerships, secondary acquisitions, co-investments, and targeted direct investments, with a recent emphasis on top-quartile managers and co-investments.
86% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $188.9M (across 7 rounds with reported amounts).
Portfolio
7
Fund Size
$85.1B
Top Stage
Series A
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
7 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Indigo Ag | Series E | $250M | Sep 2018 |
 Codiak BioSciences Inc. | Series C | $76.5M | Nov 2017 |
| Codiak BioSciences Inc. | Series A | $80M | Nov 2015 |
 Denali Therapeutics Inc. | Series D | $217M | May 2015 |
| Denali Therapeutics Inc. | Unknown | $88M | May 2015 |
 Juno Therapeutics | Series A | $176M | Apr 2014 |
| SSana Biotechnology | Growth | $435M | — |
Top Co-Investors
ARCH Venture Partners6 shared
Flagship Pioneering3 shared
Flagship Ventures3 shared
Baillie Gifford2 shared
Fidelity Biosciences2 shared
Alexandria Venture Investments2 shared
Bezos Expeditions2 shared
Qatar Investment Authority1 shared
Casdin Capital1 shared
F-Prime Capital1 shared
GV (Google Ventures)1 shared
Omega Funds1 shared
Altitude Life Science Ventures1 shared
Crestline Investors1 shared
Venrock1 shared
Last updated: 15 April 2026